论文部分内容阅读
目的 :研究P16和细胞周期蛋白D1在子宫内膜癌中的表达及其临床意义。方法 :采用免疫组化LSAB法检测 42例子宫内膜癌中P16、细胞周期素D1的表达。结果 :42例子宫内膜癌中 2 0例p16表达阳性 ,占 47 6 % ,p16与子宫内膜癌的细胞分级、临床分期、肌层浸润深度有关 (P <0 0 5 ) ;17例子宫内膜癌细胞周期素D1表达阳性 ,占 40 4% ,细胞周期素D1与子宫内膜癌的细胞分级、临床分期、淋巴结转移有关 (P <0 0 5 ) ;p16、细胞周期素D1协同表达 15例 ,均为晚期或低分化癌。结论 :p16、细胞周期素D1作为细胞周期调节因子参与子宫内膜癌的发生、发展 ,其协同作用促进子宫内膜癌的发展、且预后不良
Objective: To study the expression of P16 and cyclin D1 in endometrial carcinoma and its clinical significance. Methods: Immunohistochemical LSAB method was used to detect the expression of P16 and cyclin D1 in 42 cases of endometrial carcinoma. Results: The expression of p16 was positive in 20 of 42 cases of endometrial carcinoma, accounting for 47.6%. The expression of p16 was correlated with the cell grade, clinical stage and depth of myometrial invasion (P <0.05) The expression of cyclin D1 in endometrial carcinoma was 40.4%, and the expression of cyclin D1 was related to the cell grade, clinical stage and lymph node metastasis of endometrial carcinoma (P <0.05); the expression of p16 and cyclin D1 15 cases were advanced or poorly differentiated carcinoma. Conclusion: p16 and cyclin D1 are involved in the occurrence and development of endometrial carcinoma as cell cycle regulators, and their synergistic effects promote the development of endometrial carcinoma with poor prognosis